Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Synthetic Lethality Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAT1A/MAT2A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAT2A / MAT1A Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MAT2A Products |
| Gene Delivery | MAT2A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MAT2A Products |
| Benchmark Ab | Anti-MAT2A Biosimilar Recombinant positive control for target engagement. |
View MAT2A Products |
| Validator | MAT2A siRNA Set For knockdown verification. |
View MAT2A Products |
| Related Target A | MTAP Biomarker for synthetic lethality vulnerability. |
View MTAP Products |
| Related Target B | PRMT5 Downstream pathway target heavily dependent on SAM. |
View PRMT5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| MAT1A vs MAT2A Selectivity Screening | Human MAT1A and MAT2A ortholog proteins available with >95% purity for side-by-side screening |
| Allosteric Pocket Binding | Native-conformation preserved recombinant proteins verified by theoretical MW |
| Lack of Controls | Clinical Benchmark Antibodies included for assay baselines |
| False Positives | Validated siRNA included for specificity checks in rescue experiments |
Live MAT1A/MAT2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAT2A therapeutics is intensifying, heavily driven by the synthetic lethality paradigm in MTAP-deleted cancers (roughly 15% of all solid tumors). As first-generation small molecule allosteric inhibitors reach the clinic, the next wave of R&D is targeting optimized brain penetrance, enhanced MAT1A sparing to prevent hepatotoxicity, and rational combinations with PRMT5 inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Ideaya Biosciences | MTAP-deleted Cancers | Selectivity Assay (Need High-Purity MAT1A/MAT2A) |
| PROTAC / Degrader | Early Stage Biotech | Refractory MTAP-deleted | Ternary Complex Formation (Need purified targets) |
| Combination Tx | Amgen, Mirati | PRMT5/MAT2A Axis | Cellular Pathway Assays (Need siRNA and Lentivirus) |